Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP370686.RAQ-IyT_MTuw8to3UU0Slzg5ueaF30MQ2kEStICdpTOYE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP370686.RAQ-IyT_MTuw8to3UU0Slzg5ueaF30MQ2kEStICdpTOYE130_assertion type Assertion NP370686.RAQ-IyT_MTuw8to3UU0Slzg5ueaF30MQ2kEStICdpTOYE130_head.
- NP370686.RAQ-IyT_MTuw8to3UU0Slzg5ueaF30MQ2kEStICdpTOYE130_assertion description "[This study enrolled 63 consecutive patients with advanced EGFR-mutant NSCLC and good performance status (PS) and who underwent first-line EGFR-TKI therapy or standard cytotoxic chemotherapy and then had progressive disease, from 2007 to 2011.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP370686.RAQ-IyT_MTuw8to3UU0Slzg5ueaF30MQ2kEStICdpTOYE130_provenance.
- NP370686.RAQ-IyT_MTuw8to3UU0Slzg5ueaF30MQ2kEStICdpTOYE130_assertion evidence source_evidence_literature NP370686.RAQ-IyT_MTuw8to3UU0Slzg5ueaF30MQ2kEStICdpTOYE130_provenance.
- NP370686.RAQ-IyT_MTuw8to3UU0Slzg5ueaF30MQ2kEStICdpTOYE130_assertion SIO_000772 24633759 NP370686.RAQ-IyT_MTuw8to3UU0Slzg5ueaF30MQ2kEStICdpTOYE130_provenance.
- NP370686.RAQ-IyT_MTuw8to3UU0Slzg5ueaF30MQ2kEStICdpTOYE130_assertion wasDerivedFrom befree-20150227 NP370686.RAQ-IyT_MTuw8to3UU0Slzg5ueaF30MQ2kEStICdpTOYE130_provenance.
- NP370686.RAQ-IyT_MTuw8to3UU0Slzg5ueaF30MQ2kEStICdpTOYE130_assertion wasGeneratedBy ECO_0000203 NP370686.RAQ-IyT_MTuw8to3UU0Slzg5ueaF30MQ2kEStICdpTOYE130_provenance.